In vitro synergistic activity of diketopiperazines alone and in combination with amphotericin B or clotrimazole against Candida albicans

Folia Microbiologica

Volumn 58, Issue 6, 2013, Pages 475-482

  Kumar, S Nishanth ^a   Nambisan, Bala ^a   Mohandas, C ^a   Sundaresan, A ^b  

^a CENTRAL TUBER CROPS RESEARCH INSTITUTE   (India)

^b REGIONAL RESEARCH LABORATORY CSIR   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BACILLUS SP.; CANDIDA; CANDIDA ALBICANS; OSCHEIUS; RHABDITIS;

AMPHOTERICIN B; CLOTRIMAZOLE; PIPERAZINEDIONE;

ARTICLE; BACILLUS; CANDIDA ALBICANS; CELL LINE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECT; DRUG POTENTIATION; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY;

AMPHOTERICIN B; BACILLUS; CANDIDA ALBICANS; CELL LINE; CELL SURVIVAL; CLOTRIMAZOLE; DIKETOPIPERAZINES; DRUG SYNERGISM; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY;

EID: 84884673993     PISSN: 00155632     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12223-013-0234-x     Document Type: Article

References (45)

1. Adams ML, Kwon GS (2003) Relative aggregation state and hemolytic activity of amphotericin B encapsulated bypoly(ethylene oxide)-block-poly(N-hexyI-l-aspartamide)-acylconjugate micelles: effects of acyl chain length. J Control Release 87: 23-32.
2. Anto RJ, Venkataraman M, Karunagaran D (2003) Inhibition of NF-KB sensitizes A431 cells to epidermal growth factor-induced apoptosis, whereas its activation by ectopic expression of RelA confers resistance. J Biol Chem 28: 25490-25498.
3. Banerjee SN, Emori TG, Culver DH, Gaynes RP, Jarvis WR, Horan T (1991) Secular trends in nosocomial primary bloodstream infections in the United States, National Nosocomial Infections Surveillance System. Am J Med 91: 86-89.
4. Barchiesi F, Maracci M, Radi B, Arzeni D, Bladassarri I, Giacometti A, Scalise G (2002) Point prevalence, microbiology and fluconazole susceptibility patterns of yeast isolates colonizing the oral cavities of HIV-infected patients in the era of highly active antiretroviral therapy. J Antimicrob Chemother 50: 999-1002.
5. Beck-Sague C, Banerjee S, Jarvis WR (1993) Infectious diseases and mortality among US nursing home residents. Am J Public Health 83: 1739-1742.
6. Beringer PM (1999) New approaches to optimizing antimicrobial therapy in patients with cystic fibrosis. Cur Opinon Pul Med 5: 371-377.
7. Borisy AA, Elliott PJ, Hurst NW, Lee MS, Lehar J, Price ER, Serbedzija G, Zimmermann GR, Foley MA, Stockf BR, Keithet C (2003) Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci 100: 7977-7982.
8. Cain CC, Dongho L, Robert H, Waldo II, Alexis T, Henry EJ, Casida J, Mansukh C, Wan ME, Wall MC, Oberlies NH, Joseph OF (2003) Synergistic antimicrobial activity of metabolites produced by a non obligate bacterial predator. Antimicrob Agents Chemother 47(7): 2113-2117.
9. Cowen LE, Lindquist S (2005) Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science 309: 2185-2189.
10. Degrassi G, Aguilar C, Bosco M, Zahariev S, Pongor S, Ventur V (2002) Plant growth-promoting Pseudomonas putida WCS358 produces and secretes four cyclic dipeptides: cross-talk with quorum sensing bacterial sensors. Curr Microbiol 45: 250-254.
11. Demain AL, Zhang L (2005) In: Zhang L, Demain AL (eds) Natural products: drug discovery and therapeutics medicines. Humana, Totowa, pp 3-32.
12. Eckmanns T, Ruden H, Gastmeier P (2006) The influence of high-efficiency particulate air filtration on mortality and fungal infection among highly immunosuppressed patients: a systematic review. J Infect Dis 193: 1408-1418.
13. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP (1999) Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 29: 239-244.
14. Forst S, Nealson KH (1996) Molecular Biology of the symbiotic-pathogenic bacteria Xenorhabdus spp. and Photorhabdus spp. Microbiol 51: 47-72.
15. George M, Eliopoulos GM, Robert C, Moellering JR (1996) Antimicrobial combinations. Antibiotics in laboratory medicine. Williams and Wilkins, Baltimore, pp 330-396.
16. Ghannoum MA, Rice LB (1999) Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 12: 501-517.
17. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, Shadduck RK, Shea TC, Stiff P, Friedman DJ, Powderly WG, Silber JL, Horowitz H, Lichtin A, Wolff SN, Mangan KF, Silver SM, Weisdorf D, Ho WG, Gilbert G, Donald B (1992) A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 326: 845-851.
18. Graybill JR, Revankar SG, Patterson TF (1998) In: Ajello L, Hay RJ (eds) Topley and Wilson's microbiology and microbial infections, vol 4, 9th edn. Arnold, London, pp 163-165.
19. Heitman J (2005) A fungal achilles' heel. Science 309: 2175-2176.
20. Hindler JA (2000) Special antimicrobial susceptibility tests. In: Mahon CR, Manusalis G (eds) Text book of the diagnostic microbiology, 2nd edn. WB Saunders, Philadelphia, pp 97-104.
21. Hossain MA, Reyes GHL, Long A, Mukherjee PK, Ghannoum MA (2003) Efficacy of caspofungin combined with amphotericin B against azole-resistant Candida albicans. J Antimicrob Chemother 51: 1427-1429.
22. Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH (2004) Combination antifungal therapy. Antimicrob Agents Chemother 48: 693-715.
23. Klepser ME, Ernst EJ, Lewis RE, Ernst ME, Pfaller MA (1998) Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods. Antimicrob Agents Chemother 47: 1207-1212.
24. Kumar NS, Mohandas C, Siji JV, Rajasekharan KN, Nambisan B (2012) Identification of antimicrobial compound, diketopiperazines, from a Bacillus sp. N strain associated with a rhabditid entomopathogenic nematode against major plant-pathogenic fungi. J Appl Microbiol 113: 914-924.
25. Larocco MT, Burgert SJ (1997) Infection in the bone marrow transplant recipient and the role of the clinical microbiology laboratory in clinical transplantation. Clin Microbiol Rev 10: 277-297.
26. Lebouvier N, Pagniez F, Duflos M, Le Pape P, Na YM, Bauta LM (2007) Synthesis and antifungal activities of new fluconazole analogues with azaheterocycle moiety. Bioorg Medi Chem Lett 17: 3686-3689.
27. Lewis RE, Kontoyiannis DP (2001) Rationale for combination antifungal therapy. Pharmacother 21: 149-164.
28. Marokhazi J, Lengyel K, Pekar S, Felfoldi G, Patthy A, Graf L, Fodar A, Venekei I (2004) Comparison of proteolytic activities produced by entomopathogenic Photorhabdus bacteria: Strain- and phase-dependent heterogeneity in composition and activity of four enzymes. Appl Environ Microbiol 70: 7311-7320.
29. Martins MB, Carvalho I (2007) Diketopiperazines: biological activity and synthesis. Tetrahedron 63: 9923-9932.
30. Mccleland K, Milne PJ, Lucieto FR, Frost C, Brauns SC, van De Venter M, Du Plessis J, Dyason K (2004) An investigation into the biological activity of the selected histidine-containing diketopiperazines cyclo(His-Phe) and cyclo(His-Tyr). J Pharmacy Pharmacol 56: 1143-1153.
31. Morrell M, Fraser VJ, Kollef MH (2005) Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 49: 3640-3645.
32. Pereira-Cencil T, Del Bel Cury AA, Crielaard W, Ten Cate JM (2008) Development of Candida-associated denture stomatitis: new insights. J Applied Oral Sci 16(2): 86-94.
33. Pillai SK, Moellering RC (2005) Antimicrobial combinations. Antibiotics in laboratory medicine. Lippincott Williams and Wilkins, New York, pp 365-400.
34. Prasad C (1995) Bioactive cyclic dipeptides. Peptides 16: 151-164.
35. Rangel-Frausto MS, Wilblin T, Blumberg HM, Saiman L, Patterson J, Rinaldi M, Michael R, Michael P, John EE, William J, Jeffrey D, Wenzelet RP (1999) National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 29: 253-258.
36. Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards J, Hadley S, Brass C, Vazquez JA, Chapman S, Horowitz H, Zervos M, McKinsey D, Lee J, Babinchak T, Bradsher RW, Cleary JD, Cohen DM, Danziger L, Goldman M, Goodman J, Hilton E, Hyslop NE, Kett DH, Lutz J, Rubin RH, Scheld WM, Schuster M, Simmons B, Stein DK, Washburn RG, Mautner L, Chu T, Panzer H, Rosenstein R, Booth J (2003) A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in non neutropenic subjects. Clin Infect Dis 36: 1221-1228.
37. Rex JH, Rinaldi MG, Pfaller MA (1995) Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 39: 1-8.
38. Rhee KH (2002) Isolation and characterization of Streptomyces sp. KH-614 producing anti-VRE (vancomycin-resistant enterococci) antibiotics. J Gen Appl Microbiol 48: 327-331.
39. Rhee KH (2003) Purification and identification of an antifungal agent from Streptomyces sp. KH-614 antagonistic to rice blast fungus, Pyricularia oryzae. J Microbiol Biotechnol 13(6): 984-988.
40. Rhee KH (2004) Cyclic dipeptides exhibit synergistic, broad spectrum antimicrobial effects and have anti-mutagenic properties. Int J antimicrobial agents 24: 423-427.
41. Rosa SD, Mitova M, Tommonaro G (2003) Marine bacteria associated with sponge as source of cyclic peptides. Biomol Eng 20: 311-316.
42. Sanchez V, Vasquez JA, Barth-Jones D, Dembry L, Sobel JD, Zervus MJ (1993) Nosocomial acquisition of Candida parapsilosis: an epidemiologic study. Am J Med 94: 577-582.
43. Strom K, Sjogren J, Broberg A, Schnurer J (2002) Lactobacillus plantarum MiLAB 393 produces the antifungal cyclic dipeptides cyclo(l-Phe-l-Pro) and cyclo(l-Phe-trans-4-OH-l-pro) and 3-phenyllactic acid. Appl Environ Microbiol 68: 4322-4327.
44. Sugar AM, Alsip SG, Galgiani JN, Graybill JR, Dismukes WE, Cloud GA, Craven PC, Stevens DA (1997) Pharmacology and toxicity of high-dose ketoconazole. Antimicrob Agents Chemother 31: 1874-1878.
45. Yan PS, Song Y, Sakuno E, Nakajima H, Nakagawa H, Yabe K (2004) Cyclo(l-Leucyl-l-Prolyl) produced by Achromobacter xylosoxidans inhibits aflatoxin production by Aspergillus parasiticus. Appl Environ Microbiol 70: 7466-7473.